Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion
Advanced Science · 2026
DOI: 10.1002/advs.202521443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Sile Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, P. R. Chin…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Receptors, CCR4, Immunotherapy, Adoptive, Antigens, CD7. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Research, Collaborative Research, Research Funds from Goh Foundation, Singapore.
Abstract (Originalsprache)
The use of chimeric antigen receptor (CAR) T‐cell therapy for T‐cell malignancies is limited by fratricide, antigen‐escape, lack of functional endurance and adverse events such as multilineage cytopenia. To address these limitations, we developed a simple single‐step CD7‐depletion process followed by transduction with a lentiviral vector encoding a CCR4/CD7 bispecific CAR. CD7‐negative (CD7N) CCR4/CD7 CAR‐T cells could expand without experiencing fratricide, unlike the bulk CCR4/CD7 CAR‐T cells. The CD7N CAR‐T exhibited robust cytotoxicity against malignant T‐cell lines with heterogeneous CD7 and CCR4 expression in vitro and in vivo. Incorporation of EGFRt in the CAR construct allowed elimination by cetuximab in case of adverse events, whereas inclusion of c‐Jun in the construct reduced functional exhaustion after repeated tumor challenges in vitro. In comparison to non‐transduced CD7N cells and Bulk CAR‐T cells, scRNA‐seq analysis of CD7N CAR‐T cells revealed a unique AQP3+ CD4+ T‐cell subset following exposure to tumor cells. This cell subset exhibited broad activation of the Src/Ras/ERK and Bcl‐2 pathways, high levels of SOS1 and KLF2 expression, and specific ligand‐receptor interactions within the tumor necrosis factor superfamily. Collectively, these results suggest that further clinical development of CCR4/CD7 bispecific CD7N CAR‐T cells is warranted, including the AQP3+ subset with SOS1 / KLF2 modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, P. R. China.
- Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Kowloon, Hong Kong SAR, P. R. China.
- Children's Blood and Cancer Centre, KK Women's and Children's Hospital, SingHealth Duke-NUS, Singapore, Singapore.
ORCID-Profile: Sile Li, Hong Kee Tan, Wilson Yau Ki Chan, Wenwei Tu, Wing Leung
Förderung
- General Research
- Collaborative Research
- Research Funds from Goh Foundation, Singapore
- Intel Collaborative Research Institute on Mobile Networking and Computing
Zitieren
APA
Li, S., Li, Y., Rashid, A., Tan, H. K., Chan, S., Hui, M. Y., Chan, W. Y. K., Lam, K. S., Liu, Y., Tu, W., & Leung, W. (2026). Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion. Advanced Science. https://doi.org/10.1002/advs.202521443
Vancouver
Li S, Li Y, Rashid A, Tan HK, Chan S, Hui MY, et al. Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion. Advanced Science. 2026. doi:10.1002/advs.202521443
BibTeX
@article{Li2026,
author = {Li, Sile and Li, Yuanxin and Rashid, Asif and Tan, Hong Kee and Chan, Shing and Hui, Man Yan and Chan, Wilson Yau Ki and Lam, Kee See and Liu, Yinping and Tu, Wenwei and Leung, Wing},
title = {Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202521443}
}
EUVIMED